InnoGene Co

InnoGene Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of InnoGene Co (344860.KQ) as of Oct 19, 2026 is -17.21. In the previous year, Net Debt to Free Cash Flow Ratio was -5.87 — a change of 193.18% (lower).

Net Debt/FCF

-17.21

YoY

193.18%

Last updated:

Net Debt to Free Cash Flow Ratio of InnoGene Co is 2024 -17.21 . Net Debt to Free Cash Flow Ratio of InnoGene Co was 2023 -5.87 . It decreases by 193.18% lower compared to the previous year.

The InnoGene Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
-0.92 KRW
Jan 1, 2019
0.61 KRW
Jan 1, 2020
-0.70 KRW
Jan 1, 2021
-1.21 KRW
Jan 1, 2022
-5.41 KRW
Jan 1, 2023
-5.87 KRW
Jan 1, 2024
-17.21 KRW
The InnoGene Co Net Debt/FCF history
YEARNet Debt/FCFYoY
-17.21+193.18%
-5.87+8.59%
-5.41+345.21%
-1.21+74.61%
-0.70-213.98%
0.61-166.39%
-0.92—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InnoGene Co Stock analysis

What does InnoGene Co do? InnoGene Co Ltd is a company based in Seoul, South Korea, operating within the Consumer Staples sector and the Consumer products industry. The company has 77 employees and went public on April 27, 2020. Its website is http://www.innogene.com/. InnoGene focuses on research and development related to skin regeneration and anti-aging solutions, utilizing stem cell technology and fusion technology. The company develops and manufactures cosmetics aimed at skin regeneration and aging control. Additionally, InnoGene is involved in the manufacturing and distribution of medical devices. The company's primary activities revolve around creating products that address skin health and aging concerns, leveraging scientific research in stem cell applications. As a publicly traded entity, InnoGene operates under the ticker symbol 344860.KQ and is registered with the ISIN KR7344860002. The company's headquarters are located in Seoul, and it serves a market that values innovative skincare and medical device solutions. InnoGene's product portfolio includes both cosmetic and medical device offerings, targeting consumers interested in advanced skincare technologies. The company's operations are centered on research-driven development to enhance skin health and combat aging effects. InnoGene Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InnoGene Co stock

Net Debt to Free Cash Flow Ratio of InnoGene Co is -17.21 in 2024.

Net Debt to Free Cash Flow Ratio of InnoGene Co changed from -5.87 to -17.21, representing a 193.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio InnoGene Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's InnoGene Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — InnoGene Co

All Key Metrics — InnoGene Co